Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Web-based trial to evaluate the efficacy and safety of tolterodine ER 4 mg in participants with overactive bladder: REMOTE trial.

Orri M, Lipset CH, Jacobs BP, Costello AJ, Cummings SR.

Contemp Clin Trials. 2014 Jul;38(2):190-7. doi: 10.1016/j.cct.2014.04.009. Epub 2014 May 2.

PMID:
24792229
2.

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z.

JAMA. 2006 Nov 15;296(19):2319-28. Erratum in: JAMA. 2007 Mar 21:297(11):1195. JAMA. 2007 Oct 24;298(16):1864.

PMID:
17105794
3.

Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.

Ginsberg D, Schneider T, Kelleher C, Van Kerrebroeck P, Swift S, Creanga D, Martire DL.

BJU Int. 2013 Aug;112(3):373-85. doi: 10.1111/bju.12174.

PMID:
23826844
4.

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.

Herschorn S, Swift S, Guan Z, Carlsson M, Morrow JD, Brodsky M, Gong J.

BJU Int. 2010 Jan;105(1):58-66. doi: 10.1111/j.1464-410X.2009.09086.x.

PMID:
20132103
5.
6.

Effects of tolterodine extended release on patient perception of bladder condition and overactive bladder symptoms*.

Herschorn S, Heesakkers J, Castro-Diaz D, Wang JT, Brodsky M, Guan Z; Disease Management Study Team.

Curr Med Res Opin. 2008 Dec;24(12):3513-21. doi: 10.1185/03007990802537122 .

PMID:
19032133
7.

Which anticholinergic drug for overactive bladder symptoms in adults.

Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD005429. doi: 10.1002/14651858.CD005429.pub2. Review.

PMID:
22258963
8.

Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence.

Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z.

BJU Int. 2006 May;97(5):1003-6.

PMID:
16643482
9.

Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A; Tolterodine Study Group.

Urology. 2001 Mar;57(3):414-21.

PMID:
11248608
10.

Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.

DuBeau CE, Morrow JD, Kraus SR, Creanga D, Bavendam T.

Neurourol Urodyn. 2012 Nov;31(8):1258-65. doi: 10.1002/nau.22252. Epub 2012 Aug 20.

PMID:
22907761
11.

Investigation of the clinical efficacy and safety of pregabalin alone or combined with tolterodine in female subjects with idiopathic overactive bladder.

Marencak J, Cossons NH, Darekar A, Mills IW.

Neurourol Urodyn. 2011 Jan;30(1):75-82. doi: 10.1002/nau.20928. Epub 2010 Sep 30.

PMID:
20886571
12.

Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.

Chapple C, Herschorn S, Abrams P, Sun F, Brodsky M, Guan Z.

Eur Urol. 2009 Sep;56(3):534-41. doi: 10.1016/j.eururo.2008.11.026. Epub 2008 Nov 24.

PMID:
19070418
13.

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies.

Nitti VW, Khullar V, van Kerrebroeck P, Herschorn S, Cambronero J, Angulo JC, Blauwet MB, Dorrepaal C, Siddiqui E, Martin NE.

Int J Clin Pract. 2013 Jul;67(7):619-32. doi: 10.1111/ijcp.12194. Epub 2013 May 21.

14.
15.

A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.

Frenkl TL, Zhu H, Reiss T, Seltzer O, Rosenberg E, Green S.

J Urol. 2010 Aug;184(2):616-22. doi: 10.1016/j.juro.2010.03.147. Epub 2010 Jun 19.

PMID:
20639026
16.

Comparison of fesoterodine and tolterodine in patients with overactive bladder.

Chapple CR, Van Kerrebroeck PE, J√ľnemann KP, Wang JT, Brodsky M.

BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.

PMID:
18647298
17.

Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.

Rogers RG, Bachmann G, Scarpero H, Jumadilova Z, Sun F, Morrow JD, Guan Z, Bavendam T.

Curr Med Res Opin. 2009 Sep;25(9):2159-65. doi: 10.1185/03007990903103279.

PMID:
19601704
18.

Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial.

Homma Y, Paick JS, Lee JG, Kawabe K; Japanese and Korean Tolterodine Study Group.

BJU Int. 2003 Nov;92(7):741-7. Erratum in: BJU Int. 2004 May;93(7):1135.

PMID:
14616458
19.
20.

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group.

BJU Int. 2004 Feb;93(3):303-10.

PMID:
14764127
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk